We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Affordable POC Tests to Improve Early Cancer Detection in Low-Resource Settings

By LabMedica International staff writers
Posted on 31 Oct 2023
Print article
Image: The new research center will develop affordable global health technologies for early cancer detection (Photo courtesy of 123RF)
Image: The new research center will develop affordable global health technologies for early cancer detection (Photo courtesy of 123RF)

Cancer ranks as the first or second leading cause of early death in 134 out of 183 countries. Forecasts suggest that the global rate of cancer cases will surge by 50% between 2018 and 2040. This increase is expected to be more pronounced in countries with fewer resources and inadequate healthcare infrastructure to manage cancer effectively. While early detection and proper treatment can cure most types of cancer, existing diagnostic tests are often too complex or costly to be used in basic healthcare settings, especially in areas with limited medical services. Now, new point-of-care (POC) technologies for early cancer detection aim to bring healthcare services closer to the patient, making treatment timelier and more accessible, which could enhance outcomes in the long run.

Rice University (Houston, TX, USA) is leading a multinational collaboration, involving engineers, cancer specialists, and global health experts from three different continents. The research group has received a grant for up to five years from the National Institutes of Health to set up a leading research facility within the Texas Medical Center. The focus will be on creating cost-effective POC technologies for early cancer detection in both the United States and other nations lacking sufficient healthcare infrastructure. Named the Center for Innovation and Translation of POC Technologies for Equitable Cancer Care (CITEC), the center will operate under the umbrella of the Rice360 Institute for Global Health Technologies. Funded initially by a USD 1.3 million grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the center could receive up to USD 6.5 million over the next five years. CITEC will primarily focus on the development of POC diagnostics for oral, cervical, and gastrointestinal cancers.

“CITEC will identify needed technologies, accelerate their development, evaluate their performance and impact in diverse settings and train local users and technology developers to create and disseminate more equitable POC technologies,” said Sharmila Anandasabapathy is vice president of global health at Baylor College of Medicine.

Related Links:
Rice University

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.